A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery

Trial Profile

A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Ichorcumab (Primary) ; Apixaban
  • Indications Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TEXT-TKR
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 22 Nov 2017 Planned End Date changed from 24 Sep 2019 to 4 Oct 2019.
    • 22 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 20 Oct 2017 Planned initiation date changed from 23 Oct 2017 to 25 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top